We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+0.36%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$782M
AUM Growth
+$134M
Cap. Flow
-$119M
Cap. Flow %
-15.2%
Top 10 Hldgs %
66.62%
Holding
166
New
28
Increased
41
Reduced
46
Closed
40

Top Buys

Rank Stock Value
1
ORMP icon
Oramed Pharmaceuticals
ORMP
+$4.16M
2
NKTR icon
Nektar Therapeutics
NKTR
+$3.04M
3
VKTX icon
Viking Therapeutics
VKTX
+$1.95M
4
FOLD
Amicus Therapeutics
FOLD
+$1.63M
5
GNPX icon
Genprex
GNPX
+$1.42M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$40.1M
2
NVO
Novo Nordisk
NVO
+$19.8M
3
SSKN
Strata Skin Sciences
SSKN
+$3.45M
4
INCY icon
Incyte
INCY
+$2.77M
5
AZN icon
AstraZeneca
AZN
+$2.59M

Sector Composition

Rank Sector Weight
1 Healthcare 15.01%
2 Consumer Staples 0.29%
3 Financials 0.12%
4 Technology 0.09%
5 Materials 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRS
151
PUT
DELISTED
Amyris Inc.
AMRS
– –
-990
Closed -$633K
TBIO
152
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-12,000
Closed -$152K
IDXG
153
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
– –
-93,295
Closed -$830K
ONCE
154
CALL
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-547
Closed -$4.53M
ONCE
155
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-160
Closed -$1.32M
TSRO
156
CALL
DELISTED
TESARO, Inc.
TSRO
– –
-331
Closed -$1.47M
IMUC.WS
157
DELISTED
ImmunoCellular Therapeutics Ltd.
IMUC.WS
– –
-74,443
Closed -$1K
EGLT
158
DELISTED
Egalet Corporation
EGLT
– –
-2,134
Closed -$1K
NVIV
159
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
-226
Closed -$288K
ROSG
160
DELISTED
Rosetta Genomics Ltd.
ROSG
– –
-941,693
Closed -$19K
ZGNX
161
PUT
DELISTED
Zogenix, Inc.
ZGNX
– –
-127
Closed -$561K
CYTXW
162
DELISTED
Cytori Therapeutics Inc Warrant
CYTXW
$0 ﹤0.01%
37,793
-262,620
-87% -$2.02K
HMNY
163
CALL
DELISTED
HELIOS & MATHESON INFORMATION TECHNOLOGY INC
HMNY
– –
-965
Closed -$30K
HMNY
164
PUT
DELISTED
HELIOS & MATHESON INFORMATION TECHNOLOGY INC
HMNY
– –
-246
Closed -$8K
3 4 5 6
7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2018 Portfolio in Review

As of Q3 2018, Sabby Management held 166 positions worth $782M, up 21% from $647M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $119M in Q3 2018, closing 40 positions and reducing 46 holdings. Its most notable exit was Novo Nordisk, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 26% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Sabby Management opened a new position in Oramed Pharmaceuticals worth $3.88M.

  • Sabby Management's largest Q3 2018 buy was Oramed Pharmaceuticals: 801,242 shares worth $3.88M.
  • Sabby Management added most to Nektar Therapeutics in Q3 2018, an estimated $3.04M increase.
  • Sabby Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $40.1M.
  • Sabby Management fully exited Novo Nordisk in Q3 2018, selling an estimated $19.8M.
  • Sabby Management's ten largest holdings make up 67% of its $782M portfolio in Q3 2018.
  • Sabby Management opened 28 new positions and closed 40 in Q3 2018.
  • Sabby Management's portfolio value rose 21% quarter-over-quarter to $782M.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.